Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rio Tinto, Hancock in $1.6bn deal to develop Pilbara iron ore mine

(Sharecast News) - Rio Tinto on Tuesday announced a joint investment of $1.61bn with Hancock Prospecting to develop the Hope Downs 2 iron ore project in Western Australia's Pilbara region. The mine is expected to produce 31 million tonnes of ore a year.

Hope Downs 2 will include two new pits and be incorporated into existing infrastructure, Rio said in a statement. All regulatory and environmental approvals were in place and the first ore was scheduled to be mined in 2027, it added.

"These projects are part of our strategy to continue investing in Australian iron ore and to sustain Pilbara production for decades to come," said Rio Tinto's iron ore chief executive Simon Trott.

The mine is part of Rio's tranche of new projects aimed at ensuring continued supply from the Pilbara. During the next three years, Rio Tinto expects to invest more than $13bn on new mines, plant and equipment.

It said it had a "clear pathway" to achieve and sustain mid-term system capacity of 345 - 360 million tonnes a year from its Pilbara iron ore business, with a pre-feasibility study also underway on the Rhodes Ridge project, the region's best undeveloped iron ore deposit.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.